CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
4% Hydroquinone Topical Cream +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02977507
NCT02977507N/ACompleted

Randomized, Double-blinded, Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma

Allergan·interventional·Posted Nov 30, 2016·Updated Dec 19, 2018

In Brief

A clinical study evaluating Lytera 2.0, 4% Hydroquinone Topical Cream, and 3 other interventions for Melasma. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelasma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 30, 2016
Enrollment StartDec 13, 2016
Primary CompletionOct 9, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago

Interventions

Lytera 2.0other

Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

4% Hydroquinone Topical Creamdrug

4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

SkinMedica Facial Cleanserother

SkinMedica facial cleanser applied to the face as directed.

SkinMedica Rejuvenative Moisturizerother

SkinMedica rejuvenative moisturizer applied to the face as directed.

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreenother

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.